CoChat

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Open access
Wang, Qianyu, Shen, Xiaofei, Chen, Gang, Du, Junfeng · 2022 · Cancers

The DOI matches its Crossref record; 350 of the 350 references it cites were found in a registry or an index; 78 of the 379 sources its claims cite were checked for support.

Abstract

Colorectal cancer (CRC) is one of the leading causes of death worldwide. The 5-year survival rate is 90% for patients with early CRC, 70% for patients with locally advanced CRC, and 15% for patients with metastatic CRC (mCRC). In fact, most CRC patients are at an advanced stage at the time of diagnosis. Although chemotherapy, molecularly targeted therapy and immunotherapy have significantly improved patient survival, some patients are initially insensitive to these drugs or initially sensitive but quickly become insensitive, and the emergence of such primary and secondary drug resistance is a significant clinical challenge. The most direct cause of resistance is the aberrant anti-tumor drug metabolism, transportation or target. With more in-depth research, it is found that cell death pathways, carcinogenic signals, compensation feedback loop signal pathways and tumor immune microenvironment also play essential roles in the drug resistance mechanism. Here, we assess the current major mechanisms of CRC resistance and describe potential therapeutic interventions.

Overview

CoChat Summary

TL;DR

This narrative review surveys the molecular mechanisms by which colorectal cancer (CRC) develops primary and secondary resistance to chemotherapy, molecularly targeted therapy, and immunotherapy, spanning drug metabolism, transport, target alteration, downstream and bypass signaling, cell death pathways, and the tumor microenvironment. It catalogs preclinical and clinical strategies proposed to reverse resistance, concluding that most evidence remains preclinical and that combination therapy warrants further clinical testing.

Key findings

  • CRC prognosis is stage-dependent: 5-year survival is 90% for early CRC, 70% for locally advanced CRC, and 15% for metastatic CRC (mCRC); most patients are diagnosed at an advanced stage.
  • Resistance arises from aberrant drug metabolism/transport/targets, but also from cell death pathways, oncogenic and compensatory feedback signaling, and the tumor immune microenvironment.
  • Specific resistance drivers cited include: KRAS mutations in ~40% of mCRC; BRAF V600E prevalence of 8–10% in mCRC (occurring only in KRAS-WT tumors, with 130- to 700-fold increased BRAF kinase activity); HER2 somatic mutation/amplification in 7% of CRC (TCGA); HER3 mutations in 5.7–11% of CRC; and PI3K/AKT/mTOR pathway activation in ~20% of CRC patients.
  • Clinical reversal strategies show mixed results: necitumumab plus mFOLFOX6 improved ORR (63.6% vs. 41%) and OS (22.5 m vs. 19.2 m) versus mFOLFOX6 alone in a historical comparison; Sym004 targeted EGFR ECD-mutant cells but did not improve OS in a Phase II trial; adding PI3K inhibitors to cetuximab did not improve PFS, ORR, or OS; atezolizumab plus cobimetinib did not improve response or survival in a Phase III trial.

Methods

  • Design: narrative review of preclinical and clinical literature on CRC drug resistance mechanisms, organized by mechanism (drug metabolism, drug transport, drug targets, downstream signaling, alternative receptors, oncogenic/bypass signaling, cell death pathways, tumor microenvironment).
  • Data: no systematic search strategy, databases, or inclusion criteria are reported; evidence is drawn from cited preclinical studies (cell lines, mouse models, PDX/CDX) and clinical trials of varying phases.
  • Main analysis: qualitative synthesis, with two summary tables — Table 1 (promising strategies for reversing resistance in preclinical studies) and Table 2 (promising strategies in clinical trials, listing regimen, target, subpopulation, setting, and efficacy where reported).

Limitations

  • Stated by the paper: "most of the data are based on limited preclinical data," and larger, multi-institutional preclinical and clinical studies are needed to assess the clinical significance of the potential therapeutic targets; further clinical studies are urgently needed to evaluate combination therapy.
  • Stated by the paper: several areas remain controversial or unresolved — blocking Wnt for immune regulation "is still controversial at present," and TAM density shows contradictory associations with chemotherapy response (attributed partly to CD68 not subclassifying TAM).
  • Evident from the text: as a narrative review without a described systematic search or quality appraisal, selection of cited studies may be non-exhaustive, and several clinical efficacy figures are drawn from single-arm or cross-trial comparisons rather than randomized head-to-head data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers14122928

Cites

350 of 350 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Currently FDA-approved (red) or promising (black) anti-CRC drugs. HGF: hepatocyte growth factor; c-MET: mesenchymal-epithelial transition factor; VEGF: vascular endothelial growth factor; EGFR: epidermal growth factor receptor; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B, also known as PKB; mTOR: mammalian target of rapamycin; MEK: mitogen-activated protein kinase; ERK: extracellular signal regulated kinase; CTLA-4: cytotoxic T-lymphocyte-associated antigen 4; B7: B7 ligand; PD-1: programmed death-1; PD-L1: programmed death ligand 1; 5-FU: 5-fluorouracil; OXA: oxaliplatin.
Figure 1 Currently FDA-approved (red) or promising (black) anti-CRC drugs. HGF: hepatocyte growth factor; c-MET: mesenchymal-epithelial transition factor; VEGF: vascular endothelial growth factor; EGFR: epidermal growth factor receptor; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B, also known as PKB; mTOR: mammalian target of rapamycin; MEK: mitogen-activated protein kinase; ERK: extracellular signal regulated kinase; CTLA-4: cytotoxic T-lymphocyte-associated antigen 4; B7: B7 ligand; PD-1: programmed death-1; PD-L1: programmed death ligand 1; 5-FU: 5-fluorouracil; OXA: oxaliplatin.CC BY · PubMed Central
Figure 2 The changes of drug targets and signaling pathways lead to the development of CRC resistance. IFN-γ: interferon-γ; JAK/STAT: janus kinases/signal transducer and activator of transcription; PTEN: phosphatase and tensin homolog; APC: adenomatous polyposis coli; TP: thymine phosphorylase; OPRT: orotate phosphoribosyl-transferase; UMPS: uridine monophosphate synthetase; UMPK: UMP kinase; CES2: carboxylesterase 2; ABCB1: multi-drug resistance protein 1, MDR1, P-gp; ABCG2: breast cancer resistance protein, BCRP; ABCC1: multi-drug-resistance-associated protein 1, MRP1; UGT1A1: uridine diphosphate glucuronosyltransferase 1A1; CYP3A4: cytochrome P450-3A4.
Figure 2 The changes of drug targets and signaling pathways lead to the development of CRC resistance. IFN-γ: interferon-γ; JAK/STAT: janus kinases/signal transducer and activator of transcription; PTEN: phosphatase and tensin homolog; APC: adenomatous polyposis coli; TP: thymine phosphorylase; OPRT: orotate phosphoribosyl-transferase; UMPS: uridine monophosphate synthetase; UMPK: UMP kinase; CES2: carboxylesterase 2; ABCB1: multi-drug resistance protein 1, MDR1, P-gp; ABCG2: breast cancer resistance protein, BCRP; ABCC1: multi-drug-resistance-associated protein 1, MRP1; UGT1A1: uridine diphosphate glucuronosyltransferase 1A1; CYP3A4: cytochrome P450-3A4.CC BY · PubMed Central
Figure 3 The changes of the TME lead to the development of CRC resistance. TAM: tumor-associated macrophages; MDSC: myeloid-derived suppressor cell; CAF: tumor-associated fibroblasts; ODC: ornithine decarboxylase; CSF1: colony-stimulating factor 1; NK cell: natural killer cell; TGF-β: transforming growth factor-β; IL-6: interleukin-6; FGF: fibroblast growth factor; ARG1: arginase I; iNOS: inducible nitric oxide synthase; NO: nitric oxide.
Figure 3 The changes of the TME lead to the development of CRC resistance. TAM: tumor-associated macrophages; MDSC: myeloid-derived suppressor cell; CAF: tumor-associated fibroblasts; ODC: ornithine decarboxylase; CSF1: colony-stimulating factor 1; NK cell: natural killer cell; TGF-β: transforming growth factor-β; IL-6: interleukin-6; FGF: fibroblast growth factor; ARG1: arginase I; iNOS: inducible nitric oxide synthase; NO: nitric oxide.CC BY · PubMed Central

Verification

Claims the paper makes

54 Valid · 7 Not valid · 215 Not checked · 44 Own results and interpretations

212 more claims · 40 with their cited sources checked

Create a free account to see all 320 claims and to verify the 301 references still open.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 92

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Cited by

See all 160

Metadata

Authors
Wang, Q., Shen, X., Chen, G., & Du, J.
Affiliations
  • Shanxi Medical University (CN)
  • Nanjing Drum Tower Hospital (CN)
  • Chinese PLA General Hospital (CN)
Corresponding author
  • Chen, Gang
  • Du, Junfeng
Venue
Cancers
Publisher
MDPI AG
Published
2022-06-14
Volume
14
Issue
12
Pages
2928
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4282941681
Cited by
160
References
319
Citations by year
2026: 39 · 2025: 49 · 2024: 41 · 2023: 24 · 2022: 7
FWCI
3.70
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81970500, 81870393)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
colorectal cancer, drug resistance, metastatic colorectal cancer, chemoresistance, targeted therapy, immunotherapy resistance, drug metabolism, drug transport, cell death pathways, compensatory signaling pathways, tumor immune microenvironment, therapeutic interventions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.